Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Immuneering Corp Director's Dealing 2021

Jul 30, 2021

32973_dirs_2021-07-29_0e49fc7c-e8b7-4542-bfad-fb90812e4d2c.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Immuneering Corp (IMRX)
CIK: 0001790340
Period of Report: 2021-07-29

Reporting Person: CARPENTER ROBERT J (Director)

Holdings (Non-Derivative)

Security Shares Ownership
Class A Common Stock 606666 Direct

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Stock Option $3.01 2029-12-15 Class A Common Stock (111153) Direct
Series A Preferred Stock $ Class A Common Stock (94585) Direct
Series B Preferred Stock $ Class A Common Stock (122588) Direct

Footnotes

F1: The option vests and becomes exercisable as to 25% of the underlying shares on December 16, 2020 and then in equal monthly installments over the subsequent three years, subject to Mr. Carpenter's continued service to the Issuer's board of directors through each applicable vesting date.

F2: Each share of the Issuer's preferred stock is convertible on a one-for-one basis into shares of the Issuer's Class A common stock in certain circumstances and has no expiration date. The preferred stock will automatically convert into Class A common stock immediately prior to the closing of the Issuer's initial public offering.